Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Severe Hepatic Veno-Occlusive Disease
View Full LandscapeTarget Indication
Severe Hepatic Veno-Occlusive Disease
Clinical Trial
NCT00358501Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Defitelio
Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.
View on EMA